NCT03329950 2024-03-28A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCelldex TherapeuticsPhase 1 Completed132 enrolled
NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled
NCT02501473 2020-09-09MK-3475-174Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1/2 Terminated52 enrolled 23 charts